July 2023: Whither evidence, COI in guidelines, isotretinoin safety, SGLT2 inhibitors and Utrogestan shortage

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the July 2023 issue of DTB. They discuss evidence-based medicine, access to evidence and increasing use of press releases and social media to present evidence (https://dtb.bmj.com/content/61/7/98). They talk about the safety of isotretinoin (https://dtb.bmj.com/content/61/7/99) and review a study that assessed the accuracy of conflict of interest statements in clinical guidelines (https://dtb.bmj.com/content/61/7/100). The main review article explores the evidence for cardiac and renal effects of SGLT2 inhibitors (https://dtb.bmj.com/content/61/7/103). They begin by discussing the impact of the shortage of Utrogestan.